Serge Belanger

Carl Byrnes

Brandon Folkes

Clara Dong

Jose Lora

Yuxi Dong

- Heron Therapeutics reported **total net revenues of $38.2 million** for Q3 2025 and **$114.3 million year to date**, with an **adjusted EBITDA of $1.5 million** for the quarter and **$9.5 million year to date**.  **[0000818033_2231032_1]** 
- The company experienced a **net loss of $17.5 million** in Q3 2025, primarily due to an **$11.3 million loss on debt extinguishment**, and ended the quarter with **$55.5 million in cash and short-term investments**.  **[0000818033_2231032_4]** 
- **ZYNRELEF net sales grew 49%** year over year to **$9.3 million** in Q3 2025, and **APONVIE net sales increased 173%** year over year to **$3 million**.  **[0000818033_2231032_2]** 
- The J-code for ZYNRELEF went into effect on **October 1**, and the company plans to wind down commercialization of SUSTOL over the next 12 months due to increased market competition.  **[0000818033_2231032_1]** **[0000818033_2231032_3]** 
- Heron Therapeutics **reaffirmed its full-year net revenue guidance of $153 million-$163 million** and adjusted EBITDA guidance of **$9 million-$30 million**.  **[0000818033_2231032_4]**

Heron Therapeutics Reports Q3 2025 Financial Results with Strong Product Growth and Reaffirms Full-Year Guidance

- Heron Therapeutics generated **$38.2 million** in Net Revenue for Q3 2025 and **$114.3 million** year-to-date.  **[0000818033_2230839:4]** **[0000818033_2230839:6]** 
- **ZYNRELEF** Net Sales reached **$9.3 million**, a **49%** year-over-year increase, and **APONVIE** Net Sales were **$3.0 million**, up **173%** year-over-year in Q3 2025.  **[0000818033_2230839:4]** **[0000818033_2230839:5]** 
- The company reported **$1.5 million** in Adjusted EBITDA for Q3 2025 and **$9.5 million** year-to-date.  **[0000818033_2230839:6]** 
- Heron Therapeutics **reiterated** its 2025 Adjusted EBITDA guidance of **$9.0 million to $13.0 million**.  **[0000818033_2230839:6]**

Heron Therapeutics announces Q3 2025 results

- Heron Therapeutics reported **Q3 2025 Net Revenue of $38.2 million** and **year-to-date Net Revenue of $114.3 million**.  **[818033_18000e55c3524c3db3b79bb954cf90c5_0]**  The company **reaffirmed its 2025 Net Revenue Guidance of $153 million - $163 million** and **Adjusted EBITDA guidance of $9.0 - $13.0 million**.  **[818033_18000e55c3524c3db3b79bb954cf90c5_0]** **[818033_18000e55c3524c3db3b79bb954cf90c5_1]** 
- The company experienced significant product growth in Q3 2025, with **ZYNRELEF Net Revenue increasing by 49%** compared to Q3 2024, and **APONVIE Net Revenue growing by 173%** compared to Q3 2024.  **[818033_18000e55c3524c3db3b79bb954cf90c5_0]** **[818033_18000e55c3524c3db3b79bb954cf90c5_1]**  The Acute Care franchise revenue grew **67.2% year-over-year in Q3 2025**.  **[818033_18000e55c3524c3db3b79bb954cf90c5_1]** 
- For the three months ended September 30, 2025, Heron Therapeutics reported a **Net Loss of $17.5 million** and **Adjusted EBITDA of $1.5 million**.  **[818033_18000e55c3524c3db3b79bb954cf90c5_9]** **[818033_18000e55c3524c3db3b79bb954cf90c5_10]** 
- As of September 30, 2025, **cash, cash equivalents, and short-term investments totaled $55.5 million**.  **[818033_18000e55c3524c3db3b79bb954cf90c5_2]** **[818033_18000e55c3524c3db3b79bb954cf90c5_10]**

Heron Therapeutics Announces Q3 2025 Financial Results and Reaffirms 2025 Guidance

- Heron Therapeutics reported **Q3 2025 Net Revenue of $38.2 million** and **year-to-date revenue of $114.3 million**, while reaffirming its **2025 Net Revenue Guidance of $153 million - $163 million** and **Adjusted EBITDA guidance of $9.0 million - $13.0 million**.  **[818033_0001193125-25-263617_hrtx-ex99_1.htm:0]** 
- **ZYNRELEF Net Revenue grew 49%** in Q3 2025 compared to Q3 2024, with the launch of the Vial Access Needle (VAN) completed and a permanent J-code effective October 1, 2025.  **[818033_0001193125-25-263617_hrtx-ex99_1.htm:0]** 
- **APONVIE Net Revenue increased 173%** in Q3 2025 compared to Q3 2024, supported by increased adoption and the launch of a dedicated sales team.  **[818033_0001193125-25-263617_hrtx-ex99_1.htm:0]** 
- The company's Acute Care franchise delivered **67.2% year-over-year revenue growth** in Q3 2025.  **[818033_0001193125-25-263617_hrtx-ex99_1.htm:0]** 
- As of September 30, 2025, Heron Therapeutics held **$55.5 million** in cash, cash equivalents, and short-term investments.  **[818033_0001193125-25-263617_hrtx-ex99_1.htm:1]**

HERON THERAPEUTICS, INC. /DE/ (HRTX)